



Our solution:

- Platform-agnostic PGx services – fully tailored to your needs.
- Comprehensive coverage – from genotyping to next-generation and long-read sequencing.
- Precision across technologies – ensuring consistent, high-quality results.
- Flexible, scalable, and clinically validated – Eurofins adapts to your platform, not the other way around.
- 100% of CPIC genes of priority level A and B.
- Targeted gene amplification (TGA) step: accurate genotyping of critical genes like CYP2D6, CYP2B6 and TPMT.
- Accurate CNV calling of seven important pharmaco-genes including CYP2D6.



Ready to unlock the power of Pharmacogenomics?

Scan the QR code and see how Eurofins Genomics can help you drive precision medicine forward.

2025_1002

Powering Precision Medicine with Pharmacogenomics



Innovative Technologies

Scalable & Flexible Workflows

High-Throughput Capabilities

Quality & Accuracy Assured

EUROFINS GENOMICS — SETTING THE STANDARD IN PHARMACOGENOMICS

Eurofins Genomics proudly leads the way as the first provider of ISO 15189-accredited, clinical-grade PGx solutions. Experience true end-to-end pharmacogenomics – from sample to insight – with unmatched precision, reliability, and speed.

We're empowering personalized medicine through certified excellence and scalable innovation, helping healthcare professionals deliver the right treatment, every time.


PHARMACOGENOMICS SOLUTION

Powered by Europe's largest microarray operations with facilities based in the EU and UK



Our comprehensive portfolio that includes all Thermo Fisher and Illumina microarrays stands out by reliable turn-around times and strict confidentiality for every project including intellectual property protection.

Our sample-to-answer process provides convenient solutions:



MICROARRAYS – THE EFFECTIVE PHARMACOGENOMICS SOLUTION

Complete & easily implemented cost-effective pharmacogenomics solutions

The use of Illumina Global Screen Arrays (GSA) for pharmacogenomics analyses introduces cost-effective solutions with fast return of investment that will have a major impact on human health. It allows for optimised personalised medicine: Selection of the right medicine at the right dosage for better individual patient outcome and societal value.



Embracing the Axiom platform by Thermo Fisher Scientific provides a cost-effective, innovative solution for pharmacogenomics studies. This technology assures a prompt return on investment, with the potential to significantly enhance human health. Pharmacoscan, Pharmacofocus and Pangenomix focus on personalised medicine and serve as a cutting-edge pharmacogenomics platform, thus improving individual patient outcomes and delivering greater societal value.

ThermoFisher
SCIENTIFIC